Xsulin R Espipen 100IU contains human insulin at a concentration of 100 international units per milliliter, formulated for the management of diabetes mellitus requiring insulin therapy. This rapid-acting insulin analog is indicated for the control of hyperglycemia in patients with type 1 and type 2 diabetes when diet, exercise, and oral hypoglycemic agents alone do not provide adequate glycemic control. Administered subcutaneously, Xsulin R Espipen facilitates the uptake of glucose into peripheral tissues, thereby lowering blood glucose levels effectively. The Espipen delivery system offers precise dosing with ease of use, enhancing patient compliance and minimizing administration errors. Onset of action typically occurs within 30 minutes, with peak effects observed between 2 to 4 hours and a duration of action lasting up to 6 hours, allowing for flexible dosing in relation to meals. Regular monitoring of blood glucose is essential to adjust dosage and prevent hypoglycemia. Caution is advised in patients with renal or hepatic impairment, and concomitant use with other glucose-lowering agents should be carefully managed. Xsulin R Espipen 100IU should be stored under recommended conditions to maintain potency and efficacy. It is contraindicated in patients with hypersensitivity to human insulin or any excipients contained in the formulation.